Clinical Trial Update: A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating pemetrexed, carboplatin and bevacizumab in nonsquamous non-small cell lung cancer has completed and posted results in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-11-28